Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patritumab - Amgen/Daiichi Sankyo

X
Drug Profile

Patritumab - Amgen/Daiichi Sankyo

Alternative Names: AMG-888; U3-1287

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen; U3 Pharma
  • Developer Daiichi Sankyo Company
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Head and neck cancer
  • No development reported Breast cancer; Solid tumours

Most Recent Events

  • 28 Dec 2022 Discontinued - Phase-I for Breast cancer in Japan (IV)(Daiichi Sankyo pipeline, December 2022)
  • 28 Nov 2020 No recent reports of development identified for phase-I development in Breast-cancer in Japan (IV)
  • 07 Jan 2019 Daiichi Sankyo terminates a phase II trial in Head and neck cancer (Combination therapy, First-line therapy, Metastatic disease) in Hungary, Belgium, France, Poland, Romania, United Kingdom, Germany (IV) (NCT02633800)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top